Navigation Links
Lentigen Appoints Jim Meade as Vice President of Corporate Development
Date:6/16/2008

BALTIMORE, June 16 /PRNewswire/ -- Lentigen Corporation today announced the appointment of Jim Meade, Ph.D., CLP, as vice president of corporate development. In addition to contributing to the strategic direction of the company, Dr. Meade will be responsible for managing the development of Lentigen's partnerships, stakeholder relations, product and intellectual property portfolios, contract negotiations, and other key aspects of corporate development.

Tim Ravenscroft, CEO of Lentigen, commented, "Jim's extensive background in strategic development, opportunity evaluation, and negotiation will be an important asset to Lentigen as we continue to advance our business opportunities and collaborative relationships in biotherapeutics, vaccines and protein production."

Dr. Meade previously worked at Avalon Pharmaceuticals, where he served as vice president of business development. With more than 30 years' experience in the pharmaceutical and biotechnology industries, he has also held senior-level positions at Pharmacia, Bayer and Chiron. He holds a Ph.D. in molecular biology from the University of Texas, and is a Certified Licensing Professional and an active member of the Licensing Executives Society.

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and research applications in biotechnology and medicine. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing lentiviral vector-based products across a broad spectrum of bench to clinical applications. Partnerships include The National Institutes of Health, The University of Pennsylvania, ThermoFisher Scientific and The U.S. Army. For further information, visit http://www.lentigen.com.

Contact:

Gregory Tiberend

gtiberend@rlcinc.com

Meghan Feeks

mfeeks@rlcinc.com

Richard Lewis Communications, Inc.

212-827-0020


'/>"/>
SOURCE Lentigen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
2. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
3. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
4. Lentigen to Move Headquarters and Manufacturing to Gaithersburg
5. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
6. VIRxSYS and Lentigen Announce Litigation Settlement
7. NovaVision Appoints Medical Technology Veteran Rudy Mazzocchi as Chief Executive Officer
8. Applied Computational Technologies Appoints a New CEO
9. AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs
10. BMP Sunstone Corporation Appoints Zhiqiang Han to President and Chief Operating Officer
11. American Oriental Bioengineering Appoints Anindya Chatterjee to Chief Strategy Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):